Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Public ClinicalTrials.gov record NCT02055222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta \<=1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.
Study identification
- NCT ID
- NCT02055222
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2014
- Primary completion
- Dec 31, 2017
- Completion
- Aug 22, 2018
- Last update posted
- May 31, 2022
2014 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Pulmonary Fibrosis trials
Other public records listing Pulmonary Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07441408: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis Not yet recruiting
- NCT06162884: Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis Recruiting
- NCT07572383: Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis Recruiting
- NCT00084305: Analysis of Specimens From Individuals With Pulmonary Fibrosis Active, not recruiting
- NCT00001532: Role of Genetic Factors in the Development of Lung Disease Recruiting
- NCT06532071: Advanced Imaging for Pulmonary Fibrosis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02055222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02055222 live on ClinicalTrials.gov.